Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), the best-performing Nasdaq-traded biotech stock of 2016, is on the move again. Data from a phase II trial of its flagship cannabinoid Resunab on cystic fibrosis is due any day now. This time though, it is not just retail investors getting in front of the news. Corbus is now drawing a large amount of institutional attention from several directions.
Media coverage about Accelerate Diagnostics (NASDAQ:AXDX) has been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Accelerate Diagnostics....More>>>
U.S. equities continued their post-election surge on Monday, pushing the Dow Jones Industrial Average and the other three major stock market averages to new record highs as a group for the first time since 1999.
Investors continue to view the incoming Trump administration and its plans for big tax cuts and spending as a huge tailwind for the economy. We’re also in a period of seasonal....More>>>
Does the Wall Street bull, which turns eightnext week, have nine lives like a felinethat always seems to land on its feet despite the perils it encounters?
It sure seems like thismarket has cat-like genes.A review of the countless crises and upsetsthis rising stock market has shrugged off since it began on March 9, 2009, highlights the never-say-die resilience of this aging bull the second-longest....More>>>
Shares of Mercantile Bank Co. (NASDAQ:MBWM) have been given a consensus recommendation of “Hold” by the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating on the company. The average 1 year target price among analysts....More>>>